Targeting Receptor Tyrosine Kinases or RTKs, widely expressed transmembrane proteins that act as receptors for growth factors, neurotrophic factors, and other extracellular signaling molecules, by therapeutic monoclonal antibodies (mAbs) and antibody-drug conjugates or ADCs has met with tremendous success in clinical oncology. Today, there are numerous therapeutic monoclonal antibodies are under preclinical development.
However, the potential for moving candidate antibodies into clinical trials relies heavily on therapeutic efficacy validated by human tumor xenografts in mice. In this edition of Methods in Molecular Biology Feng L, Wang W, Yao HP, Zhou J, Zhang R, and Wang MH, describe methods used to determine therapeutic efficacy of monoclonal antibodies or antibody-drug conjugates specific to human receptor tyrosine kinase using human tumor xenografts in mice as the model.
For their study, the researchers from the Cancer Biology Research Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, 79106, USA, selected an end point designed to determine whether treatment of tumor-bearing mice with a monoclonal antibody or antibody-drug conjugates results in significant delay of tumor growth.
Published in: Methods in Molecular Biology